tallózása szerző szerint "Fahrleitner-Pammer, A"

1-2 / 2

Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial

Kendler, DL; Marin, F; Zerbini, CAF; Russo, LA; Greenspan, SL; Zikan, V; Bagur, A; Malouf-Sierra, J; Lakatos, Péter; Fahrleitner-Pammer, A; Lespessailles, E; Minisola, S; Body, JJ; Geusens, P; Moricke, R; Lopez-Romero, P (2018)

BACKGROUND: No clinical trials have compared osteoporosis drugs with incident fractures as the primary outcome. We compared the anti-fracture efficacy of teriparatide with risedronate in patients with severe osteoporosis. ...
Effects of Teriparatide Compared with Risedronate on the Risk of Fractures in Subgroups of Postmenopausal Women with Severe Osteoporosis: The VERO Trial

Geusens, P; Marin, F; Kendler, DL; Russo, LA; Zerbini, CA; Minisola, S; Body, JJ; Lespessailles, E; Greenspan, SL; Bagur, A; Stepan, JJ; Lakatos, Péter; Casado, E; Moericke, R; Lopez-Romero, P; Fahrleitner-Pammer, A (2018)

The 2-year, randomized, double-blind, active-controlled fracture endpoint VERO study included postmenopausal women with established osteoporosis, who had at least 2 moderate or 1 severe baseline vertebral fractures (VFx), ...

1-2 / 2

Keresés